FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Gull Global Ltd   2. Issuer Name and Ticker or Trading Symbol USANA HEALTH SCIENCES INC [USNA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) PO BOX N-4899, 2/F BAHAMAS FINANCIAL CTR, SHIRLEY & CHARLOTTE STREETS 3. Date of Earliest Transaction (Month/Day/Year) 02/01/2019 (Street) NASSAU, C5 BH1-1000 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/01/2019   S(1)   8,662 D $ 114.34 (2) (3) 9,886,952 (11) D   Common Stock 02/01/2019   S(1)   2,910 D $ 115.57 (3) (4) 9,884,042 D   Common Stock 02/01/2019   S(1)   8,354 D $ 116.2 (3) (5) 9,875,688 D   Common Stock 02/01/2019   S(1)   719 D $ 116.97 (3) (6) 9,874,969 D   Common Stock 02/04/2019   S(1)   1,400 D $ 114.19 (3) (7) 9,873,569 D   Common Stock 02/04/2019   S(1)   2,600 D $ 115.32 (3) (8) 9,870,969 D   Common Stock 02/04/2019   S(1)   4,555 D $ 116.32 (3) (9) 9,866,414 D   Common Stock 02/04/2019   S(1)   800 D $ 116.9 (3) (10) 9,865,614 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Gull Global Ltd PO BOX N-4899, 2/F BAHAMAS FINANCIAL CTR SHIRLEY & CHARLOTTE STREETS NASSAU, C5 BH1-1000		X

Signatures

/s/ Valarie A. Hing, Attorney in Fact		02/05/2019
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
(2)	Weighted average price. Price range in multiple transactions was $113.94 to $114.93, inclusive.
(3)	The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff of the Securities Exchange Commission information regarding the number of shares sold at each price within the ranges set forth.
(4)	Weighted average price. Price range in multiple transactions was $114.94 to $115.93, inclusive.
(5)	Weighted average price. Price range in multiple transactions was $115.94 to $116.80, inclusive.
(6)	Weighted average price. Price range in multiple transactions was $116.94 to $117.10, inclusive.
(7)	Weighted average price. Price range in multiple transactions was $113.70 to $114.68, inclusive.
(8)	Weighted average price. Price range in multiple transactions was $114.82 to $115.81, inclusive.
(9)	Weighted average price. Price range in multiple transactions was $115.82 to $116.76, inclusive.
(10)	Weighted average price. Price range in multiple transactions was $116.82 to $117.00, inclusive.
(11)	The total number of outstanding shares reflects 300 shares fewer than the total number of shares last reported as beneficially owned on a Form 4 filed on January 4, 2019, which 300 shares were sold on January 4, 2019, at an average weighted price of $115.00, with actual prices ranging from $114.71 to $115.67 (and were in addition to the sales reported on the Form 4 filed on January 4, 2019).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.